Sensei Biotherapeutics Inc to Discuss Prioritization of SNS-401-NG and SNS-VISTA Call Transcript
Good day and thank you for standing by. Welcome to the Sensei Biotherapeutics Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. (Operator Instructions)
I would now like to turn the conference over to your speaker today, Lora Pike, vice president of Investor Relations and Communications. Please go ahead.
Thank you, [Jewel]. This is Lora Pike, head of Investor Relations and Communications. Welcome everyone to our conference call.
We issued a press release this afternoon announcing the prioritization of our pipeline focused on our next generation programs. On the call with me today with prepared remarks are John Celebi, our chief executive officer; Dr. Marie-Louise Fjaellskog, our chief medical officer; and Dr. Rob Pierce, our chief scientific officer. After our brief remarks, we will be joined by Erin Colgan, our SVP of Finance, and we'll be happy to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |